Biologics in myelodysplastic syndrome-related systemic inflammatory and autoimmune diseases: French multicenter retrospective study of 29 patients.
Fiche publication
Date publication
septembre 2017
Journal
Autoimmunity reviews
Auteurs
Membres identifiés du Cancéropôle Est :
Pr TOUSSIROT Eric
Tous les auteurs :
Mekinian A, Dervin G, Lapidus N, Kahn JE, Terriou L, Liozon E, Grignano E, Piette JC, Rauzy OB, Grobost V, Godmer P, Gillard J, Rossignol J, Launay D, Aouba A, Cardon T, Bouillet L, Broner J, Vinit J, Ades L, Carrat F, Salvado C, Toussirot E, Versini M, Costedoat-Chalumeau N, Fraison JB, Guilpain P, Fenaux P, Fain O,
Lien Pubmed
Résumé
Systemic inflammatory and autoimmune diseases (SIADs) associated with myelodysplastic syndromes are often difficult to treat. Corticosteroids are efficient but only usually at high doses. The use of biologics needs to be specified.
Mots clés
Arthritis, Biologics, Corticosteroids, Myelodysplastic syndrome, Relapsing polychondritis, Vasculitis
Référence
Autoimmun Rev. 2017 Sep;16(9):903-910